Perry syndrome is a rapidly progressive, autosomal dominant, neurodegenerative disorder with onset in the fifth decade (MIM168605). The cardinal symptoms consist of parkinsonism and weight loss, often accompanied by depression, apathy and social withdrawal with suicidal attempts. Hypoventilation is a late and predominantly nocturnal feature that leads to respiratory insufficiency, insomnia and ultimately death within 2-10 years (reviewed in ref. 1) . Pathologically, Perry syndrome has been recognized as a transactive-response DNAbinding protein 43 (TDP-43) proteinopathy, although the physiological relevance of this observation is unclear 2 . Morphologically, TDP-43 and ubiquitin immunopositive inclusions are comparable to those found in amyotrophic lateral sclerosis and frontotemporal dementia. However, in Perry syndrome, TDP-43 inclusions affect the extrapyramidal system and spare both motor neurons and cortical regions 2 .
First described in two Canadian families, Perry syndrome has since been recognized in seven other families around the world 1 . Although these families were of different ancestries, we hypothesized that Perry syndrome might be caused by mutations at a single locus. In 2001, an international consortium was established with the help of local neurologists. Genealogies were constructed and clinical data and blood samples were obtained for families from Canada (605), England (396), France (395), Hawaii (originally of Japanese descent, 5), Japan (537 and 711), Turkey (513) and the United States (730) (pedigree identifiers shown in parentheses). Autopsy material was reviewed, and living affected and at-risk family members were prospectively enrolled using Brain Bank protocols approved by the Mayo Clinic institutional review board. The study was also approved by local ethical committees from each participating institution. Genes linked to parkinsonism were excluded as the cause of disease in the eight families available for study 1 .
We carried out a 4-cM genome-wide scan using DNA samples from four pedigrees (395, 605, 711 and 730) likely to be most informative for linkage. Short tandem repeat (STR) genotyping for 1,033 markers was done by deCODE genetics for a fee. Linkage analysis was done using MLINK 3 with a dominant model for two-point lod scores, and SIMWALK2 for nonparametric statistics and haplotype analysis 4 . There were only two loci with two-point lod scores 42 (y ¼ 0) with a haplotype shared by affected subjects in each individual family. These regions of suggestive linkage were a 14-cM interval between D2S2368 and D2S1777 and an 18-cM interval between D10S185 and D10S562. To maximize the information content, we saturated both loci with additional STRs at 0.5-1.0-cM resolution in all family members and reanalyzed genotypes. The potential locus on chromosome 10q23-25 became nonsignificant, whereas the locus on chromosome 2p12-14 became significantly linked (two-point lod ¼ 3.52, y ¼ 0 at D2S3046). Obligate recombinants in two families (395 and 730) narrowed the disease region to B6 cM between D2S1389 and D2S3049, a genomic interval with 46 candidate genes (Supplementary Table 1 online). Gene sequencing was done on an ABI 3730 sequencer with SeqScape v2.5 analysis software (Applied Biosystems).
All eight families with Perry syndrome were found to have one of five mutations located in exon 2 of the DCTN1 gene that segregated with disease, encoding G71R (513 and 605), G71E (395), G71A (5, 396 and 711), T72P (730) and Q74P (537) (Fig. 1) . The clinical and pathological phenotypes caused by these five substitutions are notably similar, with the exception of that of the English family (396), in which affected individuals did not show hypoventilation or weight loss 1 . Assuming that each of these mutations caused dominantly inherited disease, it was possible to obtain a maximum two-point lod ¼ 11.5, y ¼ 0 at D2S3072 and a multipoint lod ¼ 14.1, y ¼ 0 at D2S3039. With the exception of G71A found in two families of Japanese descent (5 and 711), haplotype analysis did not provide evidence of a common founder (Supplementary Table 2 online). To confirm the rarity of these mutations and provide supporting evidence for pathogenicity, we also sequenced DCTN1 exon 2 in 949 unrelated US control subjects and a panel of 475 probands of various ancestries with familial parkinsonism, including subjects from continental America, Europe, Asia and North Africa. None of the five mutations identified in Perry syndrome were found in unrelated subjects (Supplementary Table 3 online).
DCTN1 encodes the large subunit of the dynactin complex, p150 glued , which is essential in many intracellular transport functions and nonmotile processes 5 . p150 glued protein interactions are partly mediated by the N-terminal cytoskeleton-associated proteinglycine-rich (CAP-Gly) domain and the 'GKNDG' binding motif 6, 7 . This includes an affinity for C-terminal acidic-aromatic sequences found in cytoplasmic linker protein CLIP170, a-tubulin and endbinding protein 1 (ref. 6) . Notably, all five coding substitutions discovered in pedigrees with Perry syndrome affect evolutionarily conserved amino acids within or immediately adjacent to the p150 glued CAP-Gly GKNDG motif (Supplementary Fig. 1 online) .
DCTN1 G59S was previously identified in a family with distal hereditary motor neuronopathy with a distinct vocal fold paresis (laryngeal dysfunction) 8, 9 . Clinically and pathologically, this disorder is very different from Perry syndrome. The mean age at onset is typically a decade earlier, at 34 years, and it has a far longer duration, on average B17 years (range 7-31) 9 . Electrophysiologic exams in affected family members revealed chronic motor neuron denervation, and postmortem examination of the medulla in one subject showed severe reduction of hypoglossal motor neurons. Dynactin p50 subunit immunostaining revealed cytoplasmic inclusions in enlarged motor neurons and fibroblasts from affected individuals, and in DCTN1 G59S transfected cells [8] [9] [10] . In vitro, the G59S mutant showed a modestly reduced affinity for microtubules, which has been suggested to impair axonal transport 8, 10 . In contrast, in Perry syndrome, there is no evidence of motor neuron pathology; on exam, the hypoglossal nucleus (5/8 cases), motor cortex (2/8) and spinal cord (2/8) remain intact. The brunt of pathology is seen in surviving dopaminergic neurons of the substantia nigra, the locus ceruleus, dorsal raphe nucleus and respiratory neurons in the ventrolateral medulla 2, 11 . Neuronal inclusions are observed with TDP-43 immunohistochemistry and, to a lesser extent, with dynactin p62 and p50 antibodies (Fig. 2) . (Dynactin p150 antibodies are not useful for immunohistochemistry.) Although no autopsy material was available from muscle or peripheral nerve, there was no clinical indication of motor neuron disease 1 . One affected subject from US family 730, with DCTN1 T72P, developed mild polyneuropathy and muscle denervation, but this could be incidental 12 .
Functional assessment of Perry syndrome DCTN1 mutants G71R and Q74P revealed a modest decrease in microtubule binding comparable to G59S ( Supplementary Fig. 2 online) . In addition, cells transfected with DCTN1 G59S, G71R and Q74P showed a marked redistribution of dynactin compared to overexpression of wild-type protein ( Supplementary Fig. 3 online) . Together, these findings provide supporting evidence of pathogenicity. However, p150 glued is known to have at least two microtubule-binding domains with quite different physiological roles 7 . The CAP-Gly domain normally facilitates stable binding as a 'parking brake' to inhibit dynein motility; it has yet to be assessed whether G59S or Perry mutations enhance dynein processivity or 'skating' along microtubules. Substitutions in the p150 glued CAP-Gly domain may also destabilize the entire dynactin complex, promoting its degradation, of which a general consequence may be impaired misfolded protein clearance and/or aggregation. Whether dynactin in TDP-43 immunopositive inclusions is due their functional interaction or to a secondary response accompanying protein aggregation and inclusion formation should be examined in other TDP-43 proteinopathies.
In summary, mutations affecting the CAP-Gly domain of p150 glued are likely to disrupt many physiologically relevant moderate-affinity interactions of p150 glued with its binding partners 5, 6 . According to analyses of crystal structures, Gly59 is centrally located in the p150 glued CAP-Gly domain 13 . In contrast, Perry syndrome substitutions at Gly71 (with Thr72 and Gln74 adjacent) directly affect the GKNDG binding motif. The subtle differences of these mutations on binding interactions are now important to resolve, as they may underlie the selective vulnerability of distinct neuronal populations, in these different neurodegenerative diseases.
